SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc. (Amendment)

2/14/24 8:51:11 PM ET

$FDMT

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $FDMT alert in real time by email

SC 13G/A 1 tm246235d11_sc13ga.htm SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

4D Molecular Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

35104E100

(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

	¨	Rule 13d-1(b)

	x	Rule 13d-1(c)

Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 35104E100

Page 2 of 14

1.	Names of Reporting Persons Venrock Healthcare Capital Partners III, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware

Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power 0
	6.	Shared Voting Power 4,400,000 (2)
	7.	Sole Dispositive Power 0
	8.	Shared Dispositive Power 4,400,000 (2)

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,400,000 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 8.9% (3)
12.	Type of Reporting Person (See Instructions) PN

(1)	Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

(2)	Consists of (i) 1,103,763 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 110,418 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,185,819 shares held by Venrock Healthcare Capital Partners EG, L.P.

(3)	This percentage is calculated based on 49,338,467 shares of common stock outstanding as of February 9, 2024 as disclosed in the Issuer’s prospectus supplement dated February 6, 2024 filed with the Securities and Exchange Commission on February 8, 2024.

CUSIP No. 35104E100

Page 3 of 14

1.	Names of Reporting Persons VHCP Co-Investment Holdings III, LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware

Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power 0
	6.	Shared Voting Power 4,400,000 (2)
	7.	Sole Dispositive Power 0
	8.	Shared Dispositive Power 4,400,000 (2)

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,400,000 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 8.9% (3)
12.	Type of Reporting Person (See Instructions) OO

(1)	Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

(2)	Consists of (i) 1,103,763 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 110,418 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,185,819 shares held by Venrock Healthcare Capital Partners EG, L.P.

(3)	This percentage is calculated based on 49,338,467 shares of common stock outstanding as of February 9, 2024 as disclosed in the Issuer’s prospectus supplement dated February 6, 2024 filed with the Securities and Exchange Commission on February 8, 2024.

CUSIP No. 35104E100

Page 4 of 14

1.	Names of Reporting Persons Venrock Healthcare Capital Partners EG, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware

Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power 0
	6.	Shared Voting Power 4,400,000 (2)
	7.	Sole Dispositive Power 0
	8.	Shared Dispositive Power 4,400,000 (2)

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,400,000 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 8.9% (3)
12.	Type of Reporting Person (See Instructions) PN

(1)	Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

(2)	Consists of (i) 1,103,763 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 110,418 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,185,819 shares held by Venrock Healthcare Capital Partners EG, L.P.

(3)	This percentage is calculated based on 49,338,467 shares of common stock outstanding as of February 9, 2024 as disclosed in the Issuer’s prospectus supplement dated February 6, 2024 filed with the Securities and Exchange Commission on February 8, 2024.

CUSIP No. 35104E100

Page 5 of 14

1.	Names of Reporting Persons VHCP Management III, LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware

Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power 0
	6.	Shared Voting Power 4,400,000 (2)
	7.	Sole Dispositive Power 0
	8.	Shared Dispositive Power 4,400,000 (2)

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,400,000 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 8.9% (3)
12.	Type of Reporting Person (See Instructions) OO

(1)	Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

(2)	Consists of (i) 1,103,763 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 110,418 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,185,819 shares held by Venrock Healthcare Capital Partners EG, L.P.

(3)	This percentage is calculated based on 49,338,467 shares of common stock outstanding as of February 9, 2024 as disclosed in the Issuer’s prospectus supplement dated February 6, 2024 filed with the Securities and Exchange Commission on February 8, 2024.

CUSIP No. 35104E100

Page 6 of 14

1.	Names of Reporting Persons VHCP Management EG, LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware

Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power 0
	6.	Shared Voting Power 4,400,000 (2)
	7.	Sole Dispositive Power 0
	8.	Shared Dispositive Power 4,400,000 (2)

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,400,000 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 8.9% (3)
12.	Type of Reporting Person (See Instructions) OO

(1)	Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

(2)	Consists of (i) 1,103,763 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 110,418 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,185,819 shares held by Venrock Healthcare Capital Partners EG, L.P.

(3)	This percentage is calculated based on 49,338,467 shares of common stock outstanding as of February 9, 2024 as disclosed in the Issuer’s prospectus supplement dated February 6, 2024 filed with the Securities and Exchange Commission on February 8, 2024.

CUSIP No. 35104E100

Page 7 of 14

1.	Names of Reporting Persons Shah, Nimish
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization United States

Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power 0
	6.	Shared Voting Power 4,400,000 (2)
	7.	Sole Dispositive Power 0
	8.	Shared Dispositive Power 4,400,000 (2)

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,400,000 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 8.9% (3)
12.	Type of Reporting Person (See Instructions) IN

(1)	Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

(2)	Consists of (i) 1,103,763 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 110,418 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,185,819 shares held by Venrock Healthcare Capital Partners EG, L.P.

(3)	This percentage is calculated based on 49,338,467 shares of common stock outstanding as of February 9, 2024 as disclosed in the Issuer’s prospectus supplement dated February 6, 2024 filed with the Securities and Exchange Commission on February 8, 2024.

CUSIP No. 35104E100

Page 8 of 14

1.	Names of Reporting Persons Koh, Bong
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization United States

Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power 0
	6.	Shared Voting Power 4,400,000 (2)
	7.	Sole Dispositive Power 0
	8.	Shared Dispositive Power 4,400,000 (2)

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,400,000 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 8.9% (3)
12.	Type of Reporting Person (See Instructions) IN

(1)	Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

(2)	Consists of (i) 1,103,763 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 110,418 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,185,819 shares held by Venrock Healthcare Capital Partners EG, L.P.

(3)	This percentage is calculated based on 49,338,467 shares of common stock outstanding as of February 9, 2024 as disclosed in the Issuer’s prospectus supplement dated February 6, 2024 filed with the Securities and Exchange Commission on February 8, 2024.

CUSIP No. 35104E100

Page 9 of 14

Introductory Note: This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP III LP, VHCP Co-Investment III, VHCP EG and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of the Common Stock of 4D Molecular Therapeutics, Inc.

Item 1.
	(a)	Name of Issuer

		4D Molecular Therapeutics, Inc.

	(b)	Address of Issuer’s Principal Executive Offices

		5858 Horton Street #455
		Emeryville, CA 94608

Item 2.
	(a)	Name of Person Filing

		Venrock Healthcare Capital Partners III, L.P.
		VHCP Co-Investment Holdings III, LLC
		Venrock Healthcare Capital Partners EG, L.P.
		VHCP Management III, LLC
		VHCP Management EG, LLC
		Nimish Shah
		Bong Koh

	(b)	Address of Principal Business Office or, if none, Residence

		New York Office:	Palo Alto Office:

		7 Bryant Park	3340 Hillview Avenue
		23rd Floor	Palo Alto, CA 94304
		New York, NY 10018

	(c)	Citizenship

		All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

	(d)	Title of Class of Securities

		Common Stock, par value $0.0001 per share

	(e)	CUSIP Number

		35104E100

CUSIP No. 35104E100

Page 10 of 14

Item 3.	If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

	Not applicable

Item 4.	Ownership

	(a)	Amount beneficially owned as of February 9, 2024:

Venrock Healthcare Capital Partners III, L.P.	4,400,000	(1)
VHCP Co-Investment Holdings III, LLC	4,400,000	(1)
Venrock Healthcare Capital Partners EG, L.P.	4,400,000	(1)
VHCP Management III, LLC	4,400,000	(1)
VHCP Management EG, LLC	4,400,000	(1)
Nimish Shah	4,400,000	(1)
Bong Koh	4,400,000	(1)

(b)

Percent of class as of February 9, 2024:

Venrock Healthcare Capital Partners III, L.P.	8.9	%(2)
VHCP Co-Investment Holdings III, LLC	8.9	%(2)
Venrock Healthcare Capital Partners EG, L.P.	8.9	%(2)
VHCP Management III, LLC	8.9	%(2)
VHCP Management EG, LLC	8.9	%(2)
Nimish Shah	8.9	%(2)
Bong Koh	8.9	%(2)

(c)	Number of shares as to which the person has, as of February 9, 2024:

	(i)	Sole power to vote or to direct the vote:

Venrock Healthcare Capital Partners III, L.P.			0
VHCP Co-Investment Holdings III, LLC			0
Venrock Healthcare Capital Partners EG, L.P.			0
VHCP Management III, LLC			0
VHCP Management EG, LLC			0
Nimish Shah			0
Bong Koh			0

CUSIP No. 35104E100

Page 11 of 14

(ii)

Shared power to vote or to direct the vote:

Venrock Healthcare Capital Partners III, L.P.	4,400,000	(1)
VHCP Co-Investment Holdings III, LLC	4,400,000	(1)
Venrock Healthcare Capital Partners EG, L.P.	4,400,000	(1)
VHCP Management III, LLC	4,400,000	(1)
VHCP Management EG, LLC	4,400,000	(1)
Nimish Shah	4,400,000	(1)
Bong Koh	4,400,000	(1)

(iii)

Sole power to dispose or to direct the disposition of:

Venrock Healthcare Capital Partners III, L.P.			0
VHCP Co-Investment Holdings III, LLC			0
Venrock Healthcare Capital Partners EG, L.P.			0
VHCP Management III, LLC			0
VHCP Management EG, LLC			0
Nimish Shah			0
Bong Koh			0

(iv)

Shared power to dispose or to direct the disposition of:

Venrock Healthcare Capital Partners III, L.P.	4,400,000	(1)
VHCP Co-Investment Holdings III, LLC	4,400,000	(1)
Venrock Healthcare Capital Partners EG, L.P.	4,400,000	(1)
VHCP Management III, LLC	4,400,000	(1)
VHCP Management EG, LLC	4,400,000	(1)
Nimish Shah	4,400,000	(1)
Bong Koh	4,400,000	(1)

(1)

Consists of (i) 1,103,763 shares held by Venrock Healthcare Capital Partners III, L.P., (ii) 110,418 shares held by VHCP Co-Investment Holdings III, LLC and (iii) 3,185,819 shares held by Venrock Healthcare Capital Partners EG, L.P. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.

(2)

This percentage is calculated based on 49,338,467 shares of common stock outstanding as of February 9, 2024 as disclosed in the Issuer’s prospectus supplement dated February 6, 2024 filed with the Securities and Exchange Commission on February 8, 2024.

Item 5.	Ownership of Five Percent or Less of a Class

	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐

CUSIP No. 35104E100

Page 12 of 14

Item 6.	Ownership of More than Five Percent on Behalf of Another Person

	Not applicable

Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

	Not applicable

Item 8.	Identification and Classification of Members of the Group

	Not applicable

Item 9.	Notice of Dissolution of Group

	Not applicable

Item 10.	Certification

	By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

CUSIP No. 35104E100

Page 13 of 14

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2024

Venrock Healthcare Capital Partners III, L.P.		Venrock Healthcare Capital Partners EG, L.P.

By:	VHCP Management III, LLC	By:	VHCP Management EG, LLC
Its:	General Partner	Its:	General Partner

By:	/s/ Sherman G. Souther	By:	/s/ Sherman G. Souther
	Name: Sherman G. Souther		Name: Sherman G. Souther
	Its: Authorized Signatory		Its: Authorized Signatory

VHCP Co-Investment Holdings III, LLC

By:	VHCP Management III, LLC
Its:	Manager

By:	/s/ Sherman G. Souther
	Name: Sherman G. Souther
	Its: Authorized Signatory

VHCP Management III, LLC		VHCP Management EG, LLC

By:	/s/ Sherman G. Souther	By:	/s/ Sherman G. Souther
	Name: Sherman G. Souther		Name: Sherman G. Souther
	Its: Authorized Signatory		Its: Authorized Signatory

Nimish Shah

/s/ Sherman G. Souther
Sherman G. Souther, Attorney-in-fact

Bong Koh

/s/ Sherman G. Souther
Sherman G. Souther, Attorney-in-fact

CUSIP No. 35104E100

Page 14 of 14

EXHIBITS

A:	Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on May 15, 2023)

B:	Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed on May 15, 2023)

C:	Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on May 15, 2023)

Get the next $FDMT alert in real time by email

Date	Price Target	Rating	Analyst
1/13/2025	$40.00 → $15.00	Outperform → Market Perform	BMO Capital Markets
11/21/2024	$8.00	Underweight	Morgan Stanley
9/23/2024		Overweight → Neutral	Cantor Fitzgerald
4/15/2024	$45.00	Overweight	Barclays
4/15/2024	$459.00	Overweight	Barclays
2/7/2024	$81.00	Buy	Goldman
10/26/2023	$25.00	Outperform	RBC Capital Mkts
10/24/2023	$32.00	Overweight	Cantor Fitzgerald

SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for
$FDMT

$FDMT
Press Releases

Fastest customizable press release news feed in the world

4DMT Announces New Employment Inducement Grants

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Upcoming Investor Conferences

$FDMT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

4D Molecular Therapeutics downgraded by BMO Capital Markets with a new price target

Morgan Stanley initiated coverage on 4D Molecular Therapeutics with a new price target

4D Molecular Therapeutics downgraded by Cantor Fitzgerald

$FDMT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

$FDMT
Leadership Updates

Live Leadership Updates

4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board

4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates

4DMT Appoints Uneek Mehra as Chief Financial and Business Officer

$FDMT
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.

SEC Form S-8 filed by 4D Molecular Therapeutics Inc.

SEC Form 10-Q filed by 4D Molecular Therapeutics Inc.

$FDMT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Chief Legal Officer Bizily Scott

SEC Form 4 filed by Chief Executive Officer Kirn David

SEC Form 4 filed by Chief Medical Officer Kim Robert Young

$FDMT
Financials

Live finance-specific insights

4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy

4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™

4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)

SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $FDMT

$FDMT Press Releases

Fastest customizable press release news feed in the world

4DMT Announces New Employment Inducement Grants

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Upcoming Investor Conferences

$FDMT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

4D Molecular Therapeutics downgraded by BMO Capital Markets with a new price target

Morgan Stanley initiated coverage on 4D Molecular Therapeutics with a new price target

4D Molecular Therapeutics downgraded by Cantor Fitzgerald

$FDMT Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

$FDMT Leadership Updates

Live Leadership Updates

4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board

4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates

4DMT Appoints Uneek Mehra as Chief Financial and Business Officer

$FDMT SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.

SEC Form S-8 filed by 4D Molecular Therapeutics Inc.

SEC Form 10-Q filed by 4D Molecular Therapeutics Inc.

$FDMT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Chief Legal Officer Bizily Scott

SEC Form 4 filed by Chief Executive Officer Kirn David

SEC Form 4 filed by Chief Medical Officer Kim Robert Young

$FDMT Financials

Live finance-specific insights

4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy

4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™

4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)

Recent Analyst Ratings for
$FDMT

$FDMT
Press Releases

$FDMT
Analyst Ratings

$FDMT
Large Ownership Changes

$FDMT
Leadership Updates

$FDMT
SEC Filings

$FDMT
Insider Trading

$FDMT
Financials